Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
about
Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysisAbacavir-based triple nucleoside regimens for maintenance therapy in patients with HIVAbacavir-based triple nucleoside regimens for maintenance therapy in patients with HIVThe development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemicSTART or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus InfectionDual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed PatientsHIV infection and older Americans: the public health perspectiveScreening for chronic comorbid diseases in people with HIV: the need for a strategic approachHIV infection and cardiovascular diseaseMarkers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patientsHIV infection and the risk of acute myocardial infarction.Managing dyslipidemia in HIV/AIDS patients: challenges and solutionsCardiovascular Complications of HIV-Associated Immune DysfunctionWhy the communicable/non-communicable disease dichotomy is problematic for public health control strategies: implications of multimorbidity for health systems in an era of health transitionImpact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort studyInflammation, coagulation and cardiovascular disease in HIV-infected individualsWorsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective studyDifferential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray studyPredictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudineChallenges in initiating antiretroviral therapy in 2010.Cardiovascular Complications of HIV Infection.What's new for antiretroviral treatment in women with HIVAntiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasiaRisk stratification and prognosis of human immunodeficiency virus-infected patients with known or suspected coronary artery disease referred for stress echocardiography.Impact of the Data Collection on Adverse Events of Anti-HIV Drugs cohort study on abacavir prescription among treatment-naive, HIV-infected patients in Canada.Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study.Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study.Competing risk regression models for epidemiologic data.Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.Risk of myocardial infarction in parents of HIV-infected Individuals: a population-based Cohort Study.Vitamin D insufficiency and subclinical atherosclerosis in non-diabetic males living with HIVValidation of Medicaid Claims-based Diagnosis of Myocardial Infarction Using an HIV Clinical CohortRegistration of observational studies: is it time?Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?Abacavir/lamivudine combination in the treatment of HIV: a review.Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial.Microvascular Endothelial Dysfunction and Enhanced Thromboxane and Endothelial Contractility in Patients with HIV.Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir
P2860
Q21999480-6F03DEA6-E829-405C-B47D-FB0458E8239CQ24202180-7B04ACD4-6314-4BC7-9FCC-D111AFB7AB5FQ24239828-6CC0F452-B2C1-49E5-BA3F-DDB3EDE60B4AQ24655011-EE12ADC8-EFF7-4F0C-83ED-4225BB818444Q26753830-7148428F-D6FB-4F95-8310-EF68FD981428Q26768591-C60E68D1-C788-4D6C-A92D-1FA368BE3DE1Q26858824-D983D577-90B5-4FC2-A552-4CE5E453E4FEQ26866452-B7126E3D-6205-4880-8E49-9CA5233A4606Q27008915-0A4C1F07-644B-4DC5-A7FA-6914820CD762Q27024262-300D79A4-1458-43D9-80A9-E112B0049ECCQ27347231-AF7C8E14-8508-4F60-B84E-08A189DD7F34Q28084941-C5AE935F-A91B-4243-BCBA-526B4B77D6D1Q28084981-B9B9C094-E641-48F4-BA49-121F1B5E4C58Q28393479-46E88784-AE23-4976-B9B8-230E0861C7DCQ28479266-117DDF3A-DF45-4107-9734-B7863540FB1BQ28483645-1E0BD832-EE2A-49B8-ABFB-8A6C76627F91Q28483914-B2D10669-F922-4356-B7D8-FD72B3676B45Q28543075-BED445E8-A9F0-4812-A86E-C67FFB5A59CDQ28743352-ADA2A675-3B77-4247-B8FB-4ACBB0510474Q30227046-ADD396AA-79A3-4D89-805A-655C3ACFBF17Q30235920-A33422B6-63E0-40B6-B1C7-7C5B5648F363Q30391322-EAAB83B6-D56F-42E6-98BA-618596673B0CQ30430542-0B76671E-8049-438A-BF0C-8E868F99A9C9Q30457521-D5DA6BD6-240A-4AF9-A98E-F21EFF5AEEF3Q30657374-CD375B7F-D243-48C1-884B-5FD529D31CC3Q30751889-B8485821-6281-4DCC-A03C-5328D031085AQ30934548-6366D930-4293-40F7-8471-9D226731DCFBQ31118978-8D57E91B-57AC-4590-BB64-A892DB9B4ED7Q33389734-96F58853-1858-40A3-AB21-1BA8E04B3565Q33459711-F7220385-408A-4154-AF7A-20BB9CF8CC7DQ33602915-211B2479-0C08-4E45-8B2A-E56CF0EBB005Q33603728-7B06CDCE-AAEA-4C94-A81E-17B2A4AFB5A8Q33615509-3A4382C4-AD45-4DD2-9E2F-D1FEB3387173Q33618727-A04D5CFB-1FEF-45D4-A2E6-17CAC23757A2Q33636327-8BF841A8-0522-4914-AAAB-C0C14C27B616Q33649200-B608A0B7-21E6-4A42-AF0E-CC293C31874BQ33715435-F1D1E8F3-8418-4366-B2AE-3E7BC90355B4Q33759853-BACDE6EB-906A-4866-BEA5-360BE29F1407Q33792101-A755505A-7335-48E7-8028-D056E7699A80Q33812049-A6A0D911-32F8-4133-8F97-8E5790C0C55A
P2860
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of nucleoside reverse tran ...... a multi-cohort collaboration.
@en
Use of nucleoside reverse tran ...... a multi-cohort collaboration.
@nl
type
label
Use of nucleoside reverse tran ...... a multi-cohort collaboration.
@en
Use of nucleoside reverse tran ...... a multi-cohort collaboration.
@nl
prefLabel
Use of nucleoside reverse tran ...... a multi-cohort collaboration.
@en
Use of nucleoside reverse tran ...... a multi-cohort collaboration.
@nl
P2093
P2860
P50
P921
P1433
P1476
Use of nucleoside reverse tran ...... a multi-cohort collaboration.
@en
P2093
Andrew N Phillips
Antonella D'Arminio Monforte
Christian Pradier
D:A:D Study Group
Ian Weller
Nina Friis-Møller
Peter Reiss
Rainer Weber
Signe W Worm
P2860
P304
P356
10.1016/S0140-6736(08)60423-7
P407
P50
P577
2008-04-02T00:00:00Z